Chronic γ-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures

Molecular Psychiatry

Volumn 19, Issue 8, 2014, Pages 937-946

  Liebscher, S ^a,b   Page, R M ^b   Kafer K ^a   Winkler, E ^b   Quinn, K ^c   Goldbach, E ^c   Brigham, E F ^c   Quincy, D ^c   Basi, G S ^c   Schenk, D B ^d   Steiner, H ^b,e   Bonhoeffer, T ^a   Haass, C ^b,e,f   Meyer Luehmann, M ^b   Hubener M ^a  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Elan Pharmaceuticals Inc   (United States)

^d Prothena Biosciences Inc   (United States)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f Germany 3 Munich Cluster for Systems Neurology   (Germany)

Author keywords

Alzheimer's disease; APP transgenic mice; axonal boutons; dendritic spines; gamma secretase inhibitor; two photon imaging

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ELN 594; GAMMA SECRETASE INHIBITOR; GREEN FLUORESCENT PROTEIN; PRESENILIN 1; SULFONAMIDE; UNCLASSIFIED DRUG; ELN594; ENZYME INHIBITOR; QUINOLINE DERIVATIVE; SECRETASE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOID PLAQUE ASSOCIATED AXONAL BOUTON INSTABILITY; AMYLOID PLAQUE ASSOCIATED DENDRITIC SPINE INSTABILITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC SPINE; DRUG EFFECT; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; IN VIVO STUDY; LONG TERM CARE; MALE; MOUSE; NERVE CELL LESION; NERVE FIBER; NERVE SPROUTING; NONHUMAN; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SINGLE DRUG DOSE; TIME LAPSE IMAGING; TRANSGENIC MOUSE; TREATMENT DURATION; TURNOVER TIME; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; MULTIPHOTON MICROSCOPY; PATHOLOGY; PLAQUE, AMYLOID; SYNAPTOSOME;

AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; DENDRITIC SPINES; ENZYME INHIBITORS; MALE; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE, MULTIPHOTON; PLAQUE, AMYLOID; PRESENILIN-1; PRESYNAPTIC TERMINALS; QUINOLINES; SULFONAMIDES;

EID: 84905034994     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.122     Document Type: Article

References (67)

1. Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am J Pathol 1991; 138: 235-246.
2. Terry RD et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
3. Scheff SW, Price DA. Alzheimer's disease-related alterations in synaptic density: Neocortex and hippocampus. J Alzheimers Dis 2006; 9(3 Suppl): 101-115. (Pubitemid 44253303)
4. Koffie RM, Hyman BT, Spires-Jones TL. Alzheimer's disease: Synapses gone cold. Mol Neurodegener 2011; 6: 63.
5. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791.
6. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112. (Pubitemid 46432529)
7. WuHY et al. Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci 2010; 30: 2636-2649.
8. Lacor PN et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27: 796-807. (Pubitemid 46174498)
9. Cisse M et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 2011; 469: 47-52.
10. Koffie RM et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009; 106: 4012-4017.
11. Spires-Jones T, Knafo S. Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast 2012; 2012: 319836.
12. Spires-Jones TL et al. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol 2007; 171: 1304-1311. (Pubitemid 47582903)
13. Spires TL et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 2005; 25: 7278-7287. (Pubitemid 41113944)
14. Grutzendler J, Helmin K, Tsai J, Gan WB. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer's disease. Ann N Y Acad Sci 2007; 1097: 30-39. (Pubitemid 47084880)
15. Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 2004; 7: 1181-1183. (Pubitemid 39426234)
16. Bittner T et al. Amyloid plaque formation precedes dendritic spine loss. Acta Neuropathol 2012; 124: 797-807.
17. King DL, Arendash GW. Maintained synaptophysin immunoreactivity in Tg2576 transgenic mice during aging: Correlations with cognitive impairment. Brain Res 2002; 926: 58-68. (Pubitemid 34117590)
18. Boncristiano S et al. Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol Aging 2005; 26: 607-613. (Pubitemid 40228752)
19. Dong H, Martin MV, Chambers S, Csernansky JG. Spatial relationship between synapse loss and beta-Amyloid deposition in Tg2576 mice. J Comp Neurol 2007; 500: 311-321. (Pubitemid 44937125)
20. Steiner H, Fluhrer R, Haass C. Intramembrane proteolysis by gamma-secretase. J Biol Chem 2008; 283: 29627-29631.
21. Yan P et al. Characterizing the appearance and growth of amyloid plaques in APP/ PS1 mice. J Neurosci 2009; 29: 10706-10714.
22. Best JD et al. The novel gamma secretase inhibitor N-[cis-4-[(4- chlorophenyl) sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-Trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 2007; 320: 552-558. (Pubitemid 46147933)
23. Radde R et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006; 7: 940-946. (Pubitemid 44523975)
24. Feng G et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000; 28: 41-51.
25. Truong AP et al. Design, synthesis, and structure-Activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors. Bioorg Med Chem Lett 2009; 19: 4920-4923.
26. Meyer-Luehmann M et al. Rapid appearance and local toxicity of amyloidbeta plaques in a mouse model of Alzheimer's disease. Nature 2008; 451: 720-724. (Pubitemid 351220570)
27. Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008; 59: 214-225. (Pubitemid 352033686)
28. Liebscher S, Meyer-Luehmann MA. Peephole into the brain: Neuropathological features of Alzheimer's disease revealed by in vivo two-photon imaging. Front Psychiatry 2012; 3: 26.
29. Trachtenberg JT et al. Long-Term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature 2002; 420: 788-794. (Pubitemid 36019621)
30. Holtmaat AJ et al. Transient and persistent dendritic spines in the neocortex in vivo. Neuron 2005; 45: 279-291. (Pubitemid 40128121)
31. Hofer SB, Mrsic-Flogel TD, Bonhoeffer T, Hübener M. Experience leaves a lasting structural trace in cortical circuits. Nature 2009; 457: 313-317.
32. Pan F, Aldridge GM, Greenough WT, Gan WB. Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome. Proc Natl Acad Sci USA 2010; 107: 17768-17773.
33. De Paola V et al. Cell type-specific structural plasticity of axonal branches and boutons in the adult neocortex. Neuron 2006; 49: 861-875. (Pubitemid 43376083)
34. Knott GW, Holtmaat A, Wilbrecht L, Welker E, Svoboda K. Spine growth precedes synapse formation in the adult neocortex in vivo. Nat Neurosci 2006; 9: 1117-1124. (Pubitemid 44306304)
35. Moehlmann T et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci USA 2002; 99: 8025-8030. (Pubitemid 34650999)
36. Czirr E et al. Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J Biol Chem 2007; 282: 24504-24513. (Pubitemid 47347550)
37. Bittner T et al. Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci 2009; 29: 10405-10409.
38. Harris KM, Stevens JK. Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: Serial electron microscopy with reference to their biophysical characteristics. J Neurosci 1989; 9: 2982-2997. (Pubitemid 19214329)
39. Kasai H, Fukuda M, Watanabe S, Hayashi-Takagi A, Noguchi J. Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci 2010; 33: 121-129.
40. Loewenstein Y, Kuras A, Rumpel S. Multiplicative dynamics underlie the emergence of the log-normal distribution of spine sizes in the neocortex in vivo. J Neurosci 2011; 31: 9481-9488.
41. Xu T et al. Rapid formation and selective stabilization of synapses for enduring motor memories. Nature 2009; 462: 915-919.
42. Yang G, Pan F, Gan WB. Stably maintained dendritic spines are associated with lifelong memories. Nature 2009; 462: 920-924.
43. Gandy S, Dekosky ST. 2012: The year in dementia. Lancet Neurol 2013; 12: 4-6.
44. Busche MA et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 2008; 321: 1686-1689.
45. Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004; 63: 1155-1162. (Pubitemid 39350010)
46. Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-Term synaptic plasticity. Nature 1999; 399: 66-70.
47. Yuste R, Bonhoeffer T. Morphological changes in dendritic spines associated with long-Term synaptic plasticity. Annu Rev Neurosci 2001; 24: 1071-1089. (Pubitemid 32695254)
48. Harvey CD, Svoboda K. Locally dynamic synaptic learning rules in pyramidal neuron dendrites. Nature 2007; 450: 1195-1200.
49. De Roo M, Klauser P, Muller D. LTP promotes a selective long-Term stabilization and clustering of dendritic spines. PLoS Biol 2008; 6: E219.
50. Harnett MT, Makara JK, Spruston N, Kath WL, Magee JC. Synaptic amplification by dendritic spines enhances input cooperativity. Nature 2012; 491: 599-602.
51. Hong S et al. Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. J Neurosci 2011; 31: 15861-15869.
52. Shankar GM et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
53. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192: 106-113.
54. Cruz-Martin A, Crespo M, Portera-Cailliau C. Delayed stabilization of dendritic spines in fragile X mice. J Neurosci 2010; 30: 7793-7803.
55. Grillo FW et al. Increased axonal bouton dynamics in the aging mouse cortex. Proc Natl Acad Sci USA 2013; 110: E1514-E1523.
56. Mostany R, Anstey JE, Crump KL, Maco B, Knott G, Portera-Cailliau C. Altered synaptic dynamics during normal brain aging. J Neurosci 2013; 33: 4094-4104.
57. Grunditz A, Holbro N, Tian L, Zuo Y, Oertner TG. Spine neck plasticity controls postsynaptic calcium signals through electrical compartmentalization. J Neurosci 2008; 28: 13457-13466.
58. Araya R, Eisenthal KB, Yuste R. Dendritic spines linearize the summation of excitatory potentials. Proc Natl Acad Sci USA 2006; 103: 18799-18804. (Pubitemid 44913490)
59. Oddo S et al. Triple-Transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421. (Pubitemid 36937044)
60. Bittner T et al. Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS One 2010; 5: E15477.
61. Lanz TA et al. The gamma-secretase inhibitor N-[N-(3,5- difluorophenacetyl)-Lalanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 2003; 305: 864-871. (Pubitemid 36617962)
62. Abramowski D et al. Dynamics of Abeta turnover and deposition in different betaamyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 2008; 327: 411-424.
63. Hefendehl JK et al. Long-Term in vivo imaging of beta-Amyloid plaque appearance and growth in a mouse model of cerebral beta-Amyloidosis. J Neurosci 2011; 31: 624-629.
64. Cohen AD et al. Anti-Amyloid effects of small molecule abeta-binding agents in PS1/APP Mice. Lett Drug Des Discov 2009; 6: 437.
65. Busche MA et al. Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2012; 109: 8740-8745.
66. Ables JL, Breunig JJ, Eisch AJ, Rakic P. Not(ch) just development: Notch signalling in the adult brain. Nat Rev Neurosci 2011; 12: 269-283.
67. Martone RL et al. Begacestat (GSI-953): A novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 2009; 331: 598-608.